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The SDF-1 3′A allelic polymorphism has been reported to influence either positively or
negatively the progression of human immunodeficiency virus type 1 (HIV-1) disease. There-
fore, the SDF-1 genotype of 729 HIV-1–infected individuals pooled from 3 distinct cohorts
was determined. A statistically nonsignificant association between the SDF1-3′A/3′A genotype
and accelerated disease progression was evident among seroconverters ( ), but a strikingn = 319
correlation of decreased survival after either diagnosis of AIDS according to the 1993 defi-
nition or loss of CD4+ T cell counts !200 was observed. The relative hazards for SDF1-3′A/
3′A homozygotes, compared with heterozygotes and wild-type homozygotes were 2.16 (P =
), for time from diagnosis according to the 1993 Centers for Disease Control and Pre-.0047
vention AIDS case definition (AIDS-’93) to death, and 3.43 ( ), for time from CD4+P = .0001
T cells !200 to death. Because no difference in survival was observed after diagnosis according
to AIDS-’87, the association of the SDF1-3′A/3′A genotype with the accelerated progression
of late-stage HIV-1 disease appears to be explained for the most part by the loss of CD4+ T
lymphocytes.
An increasing number of genetic polymorphisms of che-
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mokine and chemokine-receptor genes have been related to
both the risk of human immunodeficiency virus type 1 (HIV-
1) transmission and disease progression (for review, see [1]). A
polymorphism in conserved sequences of the 3′ untranslated
region of the gene encoding the CXC chemokine SDF1-b
(SDF1-3′A), the unique ligand of the HIV-1 coreceptor CXCR4,
was reported to delay the onset of AIDS when present in the
homozygous configuration, particularly in late-stage HIV-1 dis-
ease [2]. The authors proposed that this polymorphism could
result in the increased production of SDF-1, thereby preventing
the appearance of more aggressive X4 HIV-1 [2]. These obser-
vations were not confirmed, however, in a cohort of 1090 sub-
jects from the US Tri-Service HIV Natural History Study [3]
and in 344 cases from the Amsterdam cohort [4]. In the Tri-
Service cohort, SDF1-3′A/3′A subjects showed a significantly
accelerated disease progression toward death and a weakly sig-
nificant worsening of progression to AIDS, using the 1987 Cen-
ters for Disease Control and Prevention (CDC) AIDS case
definition (AIDS-’87) [5]. These conflicting observations may
depend, at least in part, on the low frequency of the SDF1-3′A/
3′A genotype among whites (4%–5%) [2].
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In the present study, we investigated the association of SDF1
genotype on disease progression and survival in 729 seropositive
patients enrolled in 3 distinct cohorts.
Methods
Study cohorts. The San Francisco Men’s Health Study is a
population-based cohort of 1,034 single, mostly white men enrolled
in San Francisco showing the highest AIDS incidence in 1984 and
followed every 6 months until 1995. Genotyping was available for
424 individuals, of whom 377 were seroprevalents. In addition, 249
infected individuals from the Swiss HIV Cohort (SHC) and 56 long-
term nonprogressors (LTNPs) of the Milan cohort were included
in the study.
The individuals were followed for a median of 8.23, 7.61, and
12 years in the SFMHS, SHC, and Milan cohorts, respectively,
and their median ages were 34, 25, and 23.5 years. There were 1,
83, and 26 intravenous drug users; 416, 95, and 15 male homo-
sexuals; 0, 69, and 3 heterosexuals, and 0, 2, and 12 hemophiliacs
in the SFMHS, the SHC, and the Milan cohorts, respectively. There
were 661 whites, 22 Hispanics, and 26 blacks.
The following end points were considered for the analysis: (1)
CD41 T cell counts !200 cells/mL; (2) the AIDS-’87 case definition
[5]; (3) the 1993 CDC AIDS case definition (AIDS-’93), adding the
loss of CD41 T lymphocytes !200 cells/mL to the AIDS defining
conditions of AIDS-’87; and (4) death.
Plasma HIV-1 RNA concentrations were available from 674 sub-
jects [6, 7]. Viral isolation and phenotyping were performed as
described elsewhere [8, 9].
CCR5 and CCR2 genotyping. The CCR2 and CCR5 genotypes
were determined as described elsewhere for the SFMHS cohort [6,
8] and for the SHC and Milan cohorts [7, 10].
SDF1 genotyping. Subjects from the SFMHS cohort were
genotyped by polymerase chain reaction (PCR)—restriction frag-
ment length polymorphism (RFLP), as reported elsewhere [2].
For the SHC and Milan cohorts, an allelic discrimination assay
based on the allele-specific degradation of 2 internally quenched
fluorescent probes during the PCR reaction was used [11]. Wild-
type–specific probe sequence was 5′-(FAM) AGG CAG ACC
CGG CTC CCA TG (TAMRA)-3′, where FAM is 6-carboxyflu-
orescein, and TAMRA is 6-carboxytetramethylrhodamine; the
SDF1-3′A–specific probe sequence was 5′-(TET) AAG AGG
CAG ACC TGG CTC CCA TGT (TAMRA)-3′, where TET is
tetrachloro-6-carboxy-fluorescein. The primer sequences were
(sense) 5′-CCA GTC AAC CTG GGC AAA G-3′ and (antisense)
5′-TGC CTC AGC TCA GGG TAG C-3′. The PCR reaction was
performed according to the manufacturer’s instructions on an
ABI PRISM 7700 Sequence Detector System (PE Biosystems,
Foster City, CA) and the dedicated TaqMan PCR Core Reagent
Kit (PE Biosystems, Foster City, CA); the 1/1 specific probe (200
nM), the 30 A–specific probe (100 nM), the 2 primers (0.25 mM
each), and 100–200 ng of DNA were extracted from peripheral
blood mononuclear cells. Some test samples, plus all samples
without a clear-cut signal level in at least 1 of the 2 fluorescent
signals, were also characterized by the published PCR-RFLP
method [2] as control; all of the 80 doubly tested genotype as-
signments were concordant.
Statistical analysis. Departures from Hardy-Weinberg equilib-
rium and differences in categorical variables were assessed by x2
test or Fisher’s exact test when appropriate. Plasma HIV-1 RNA
levels were log transformed before analysis and compared with
SDF1 genotype by covariance analysis. The time elapsed before
reaching different immunological and clinical end points was an-
alyzed by use of Kaplan-Meier survival curves and the Cox pro-
portional-hazard regression models.
Results
SDF1 genotype distribution. Twenty-two (5%) SFMHS
participants were homozygous for SDF1-3′A/3′A, whereas 135
(32%) were heterozygous, and 267 (63%) were SDF1 1/1. In
the SHC, SDF1-3′A homozygosity was found in 12 (4.8%) sub-
jects and heterozygosity in 76 (30.5%) subjects, whereas 161
subjects were SDF1 1/1; in the Milan cohort, the frequencies
were 3 (5%), 26 (46%), and 27 (48%) for 3′A/3′A, 1/3′A, and
1/1, respectively. Each cohort and the grouped study popu-
lation were in Hardy-Weinberg equilibrium (P values ranging
from .304 to .439; x2 test). Genotype distribution and the effects
of other genetic polymorphisms involved in HIV disease pro-
gression (CCR5-D32 and CCR2-64I) of these cohorts have been
published elsewhere [6–8, 10].
SDF1 genotype and progression to AIDS. All the statistics
were stratified by cohort, to correct for potential hidden con-
founding factors. Kaplan-Meier survival curves of the com-
bined cohorts with the results of univariate Cox proportional
hazards analyses are shown in table 1. Because the same pattern
of progression was consistently observed in both SDF1-1/1
and SDF1-1/3′A individuals, these two groups were analyzed
together. A modest increase in the relative hazard (RH) for
SDF1-3′A/3′A individuals was observed when AIDS-’87 and
death were considered as end points, but the differences were
not significant. When the analyses were repeated exclusively on
the seroconverter subset (table 1), as suggested elsewhere [12],
the RH of the homozygous genotype on the various end points
was stronger, although still not significant (figure 1).
All the analyses were repeated after adjustment for CCR5
and CCR2 genotypes, age, risk factor, race, therapy, and seroin-
cidence status (i.e., seroprevalents vs. seroconverters). After
these adjustments, the overall association of SDF1-3′A/3′A on
disease progression did not change (table 1), although a further
increase of the RH of SDF1-3′A/3′A seroconverters was noted.
SDF1 genotype and survival after AIDS diagnosis. We next
tested whether the SDF1 genotype could influence the late
stages of infection, by analyzing survival after diagnosis of
AIDS according to either AIDS-’87, AIDS-’93, or loss of cir-
culating CD41 T lymphocytes !200 cells/mL. A gradation of
survival reduction was observed for time to death after AIDS-
’87, AIDS-’93, and CD41 T cell counts !200, with RH values
of 1.19 ( ), 2.21 ( ), and 3.18 ( ), re-P = .522 P = .0034 P = .0003
spectively (table 1 and figure 1). Thus, RH values increased
and gained significance shifting from AIDS-’87 to CD41 T cell
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Table 1. Effects of the SDF1-3′A/3′A genotype on progression to AIDS and from AIDS to death in
Cox proportional hazard analyses.
End point
SDF1-3′A/3′A vs. 3′A/1 and 1/1 SDF1-3′A/3′A vs. 3′A/1 and 1/1a
n Events RH CI P n Events RH CI P
CD4!200
All 692 314 0.84 0.48–1.47 .539 681 310 0.761 0.44–1.33 .339
Seroconverters 315 99 1.46 0.58–3.69 .418 314 99 1.65 0.66–4.14 .282
AIDS-’93
All 699 380 1.08 0.68–1.72 .744 688 375 1.01 0.63–1.60 .980
Seroconverters 318 114 1.56 0.67–3.61 .299 317 114 1.81 0.78–4.18 .166
AIDS-’87
All 705 311 1.27 0.78–2.07 .337 693 306 1.21 0.74–1.98 .450
Seroconverters 319 71 1.87 0.67–5.19 .232 318 71 2.23 0.79–6.30 .131
Death
All 711 273 1.26 0.75–2.12 .388 699 268 1.18 0.70–1.99 .543
Seroconverters 319 49 2.06 0.63–6.76 .234 318 49 2.38 0.70–8.04 .163
Time to death since
AIDS-’87 309 261 1.19 0.70–2.00 .522 304 256 1.13 0.67–1.91 .648
AIDS-’93 374 259 2.21 1.30–3.75 .0034 369 255 2.16 1.27–3.68 .0047
CD4 !200 314 211 3.18 1.71–5.92 .0003 310 208 3.43 1.83–6.45 .0001
NOTE. AIDS-’87, 1987 Centers for Disease Control and Prevention (CDC) AIDS case definition; AIDS-’93, 1993
CDC AIDS case definition; CI, 95% confidence interval; RH, relative hazard.
a Adjusted for CCR5 and CCR2 genotypes, age, risk factor, race (categorized as whites vs. other races), therapy, and
seroincidence status (only for the first 4 end points and for the entire data set).
counts !200. Adjusting the analysis for the same confounding
factors above described did not alter the results (table 1).
SDF1 genotype and viral phenotype. Because SDF-1 binds
to CXCR4, we tested whether the SDF1-3′A genotype could
influence viral evolution from nonsyncytium-inducing (NSI) to
syncytium-inducing (SI) strains (i.e., from CCR5 to CXCR4
usage). Ninety-three NSI viruses versus 49 SI were isolated in
a sample of 142 SDF1-1/1 patients. Among 70 SDF1-1/3′A
patients, 48 had NSI and 22 had SI viruses, whereas among
15 SDF1-3′A/3′A patients, 11 had NSI and 4 had SI viruses
(data not shown). The differences among these frequencies are
not significant ( , x2 test), which suggests that the SDF1P = .780
genotype did not influence the phenotype of HIV-1 primary
isolates.
SDF1 genotype and viremia. A single plasma HIV-1 RNA
level determination was available for each subject; the median
viral loads were 30,200, 23,174, and 5688 copies of HIV-1 RNA/
mL for the SFMHS, the SHC, and the Milan cohorts, respec-
tively. We compared the mean log transformed values of viremia
adjusting for cohort, because they differed in terms of time
from enrollment of the titered sample. Like viral phenotype,
this parameter was not influenced by the SDF1 genotype
( , covariance analysis; data not shown).P = .223
Discussion
In the present study, we have demonstrated that SDF1-3′A/
3′A homozygosity weakly accelerates HIV-1 disease progres-
sion, a result consistently observed by all the clinical end points
considered. More important, this genotype was linked to a
shorter survival from the time of AIDS diagnosis to death if
CD41 T cell counts !200 were included among the diagnostic
criteria.
The effect of the SDF1 genotype on survival of HIV-1–in-
fected subjects is highly controversial, ranging from delay to
acceleration of the disease progression [2–4]. Because these dis-
crepancies are likely influenced by the low frequency of SDF1-
3′A/3′A whites, the analysis of multiple cohorts, as here re-
ported, should help clarify this issue. The SDF1 genotype was
tested against various markers of disease progression. We found
a trend toward faster progression for SDF1-3′A/3′A individuals,
compared with SDF11/3′A and 1/1 subjects. This trend was
more pronounced when only seroconverters were considered.
In this regard, the confounding effect of seroprevalents in stud-
ies on the role of CCR5 and CCR2 genotypes on disease pro-
gression has been discussed elsewhere [12]. In contrast to Wink-
ler et al. [2], but consonant with the results reported here, two
reports [3, 4] have elsewhere described an association of the
SDF1-3′A homozygous genotype with accelerated disease pro-
gression. Of note, when analyses were performed on a cohort
whose design mitigated confounding variables [3], the associ-
ation with accelerated progression was clearly visible. The re-
cently reported role of race-specific CCR5 haplotypes on HIV-
1 pathogenesis further underscores the importance of
controlling for confounding factors [13].
We observed a strong association between the SDF1-3′A/3′A
genotype and survival reduction after either AIDS-’93 or CD41
T cell counts !200. In contrast, all the SDF1 genotypes were
indistinguishable with respect to survival after AIDS-’87. We
interpret this association as a linkage between the SDF1-3′A/
3′A genotype and the progressive immunodeficiency occurring
after erosion of CD41 T lymphocytes !200 cells/mL, resulting
in increasing incidence of opportunistic infections and tumors.
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Figure 1. SDF1-3′A/3′A genotype and time from AIDS to death.
The thick line represents SDF1-1/1 plus SDF1-1/3′A subjects, and
the thin line represents SDF1-3′A/3′A subjects. P values were based on
the Cox proportional-hazards model (univariate test), with data strat-
ified by cohort. Summary statistics are shown in table 1. AIDS-’87,
1987 Centers for Disease Control and Prevention (CDC) AIDS case
definition; AIDS-’93, 1993 CDC AIDS case definition; RH, relative
hazard.
In support of this interpretation, HIV disease progression in
seroconverters with peripheral CD41 T cell counts 1200 cells/
mL was not significantly accelerated ( ; ).RH = 1.65 P = .282
When a multivariate analysis with stepwise selections of the
variables was performed, only the SDF1-3′A/3′A genotype was
identified as a prognosticator of disease progression after
AIDS-’93 or CD41 T cell counts !200 ( andP = .0003 P =
, respectively), whereas other strong predictors of pro-.0006
gression, such as plasma HIV RNA and viral phenotype, were
forced out of the model.
Unlike CCR5-D32, the biological correlates of the SDF1-3′A/
3′A genotypes are currently unknown. Since SDF-1 is the
unique ligand of CXCR4, it can be speculated that an altered
expression consequent to the recessive genotype could influence
the evolution of HIV quasi species in vivo by changing the rate
of NSI/SI viral variants. In this regard, we and others [14] have
observed that CCR2-64I, both in heterozygotic and homozy-
gotic configuration, was positively correlated to a predomi-
nance of SI over NSI variants in 2 (SFMHC and Milan cohorts)
of the 3 cohorts here studied (authors’ unpublished data). In
contrast, no correlation was observed between SDF1 genotypes
and prevalence of SI/NSI primary isolates, which confirms pre-
vious reports [10, 15]. Because immunological parameters, in-
cluding CD41 T cell counts and concentrations of soluble cy-
tokine receptors and neopterin, are reported to be stronger
predictors of disease progression than viremia in advanced in-
fection [16], we believe that the influence of the SDF1-3′A allelic
variant on disease progression is more likely related to the im-
mune mechanisms responsible for, or affected by, CD41 T cell
depletion than to viral replication per se.
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